Dr. Doris Chen
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Nevada School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 243
Licensed in California since 2016, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of Nevada School of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license A146027 (first issued 2016; current) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of California Davis Medical Center Sacramento, CA
- John Muir Medical Center - Walnut Creek Campus Walnut Creek, CA
Medical groups
- Regents of the Univ of Ca (1,584 clinicians)
- Regents of the University of California (567 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 243
- Services billed
- 536
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 229 | 120 |
| Established patient office or other outpatient visit, 40-54 minutes | 228 | 181 |
| New patient office or other outpatient visit, 60-74 minutes | 131 | 131 |
| Established patient office or other outpatient visit, 30-39 minutes | 69 | 61 |
| New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
| Established patient office or other outpatient visit, 20-29 minutes | 12 | 12 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Memantine Hcl Other prescribers in Sacramento, CA | 210 |
| Donepezil Hcl Other prescribers in Sacramento, CA | 177 |
| Quetiapine Fumarate Other prescribers in Sacramento, CA | 44 |
| Escitalopram Oxalate Other prescribers in Sacramento, CA | 37 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Sacramento, CA | 31 |
| Rivastigmine Other prescribers in Sacramento, CA | 23 |
| Memantine Hcl Er (memantine hcl) Other prescribers in Sacramento, CA | 20 |
| Sertraline Hcl Other prescribers in Sacramento, CA | 18 |
| Rivastigmine (rivastigmine tartrate) Other prescribers in Sacramento, CA | 17 |
| Trazodone Hcl Other prescribers in Sacramento, CA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $146 in total to this clinician.
| Eisai Inc. | $146 |
|---|
| Food and Beverage | $146 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $346,723 in research payments for these studies, mostly to the institutions running them.
- A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) an…
Eisai Inc. - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06268886
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.